The effects of improved glycemic control on complications in type 2 diabetes

Archives of Internal Medicine

Volumn 158, Issue 2, 1998, Pages 134-140

  Gaster, Barak ^a   Hirch, Irl B ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PLACEBO;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; WEIGHT GAIN;

BLOOD GLUCOSE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 0031975069     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.2.134     Document Type: Review

References (121)

1. Kenny SJ, Aubert RC, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Rieber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health; 1995:47.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. Janes GR. Ambulatory medical care for diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Rieber GE, Bennett PH, eds. Diabetes in America. 2nd ed, Bethesda, Md: National Institutes of Health; 1995: 548.
4. Marrero DG. Current effectiveness of diabetes health care in the U.S. Diabetes Rev. 1994;2:292-307.
5. Peterson KA. Diabetes care by primary care physicians in Minnesota and Wisconsin. J Fam Pract. 1994;38:361-367.
6. Weiner JP, Parente ST, Garnick DW, Fowles J, Lawthers AG, Palmer RH. Variation in office-based quality: a claims-based profile of care provided to Medicare patients with diabetes. JAMA. 1995;273:1503-1508.
7. Lee ET, Lee VS, Lu M, Russell D. Development of proliferative retinopathy in NIDDM: a follow-up study of American Indians in Oklahoma. Diabetes. 1992;41:359-367.
8. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM: San Luis Valley Diabetes Study. Diabetes. 1989;38:1231-1237.
9. Howard-Williams J, Hillson RM, Bron A, Awdry P, Mann JI, Hockaday TD. Retinopathy is associated with higher glycaemia in maturity-onset type diabetes. Diabetologia. 1984;27:198-202.
10. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154:2169-2178.
11. Borch-Johnsen K, Nissen H, Henriksen E, et al. The natural history of insulin-dependent diabetes mellitus in Denmark, I: long-term survival with and without late diabetic complications. Diabet Med. 1987; 4:201-210.
12. Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int. 1989;35: 681-687.
13. Knowler WC, Kunzelman CL. Population comparisons of the frequency of nephropathy. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. Boston, Mass: Marinus Nijhoff Publishing; 1988:25-32.
14. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78:785-794.
15. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496-501.
16. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333:89-94.
17. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39:1116-1124.
18. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150-154.
19. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824
20. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-1162.
21. Ochi JW, Melton LJ III, Palumbo PJ, Chu CP. A population-based study of diabetes mortality. Diabetes Care. 1985;8:224-229.
22. Bender AP, Sprafka JM, Jagger HG, Muckala KH, Martin CP, Edwards TR, Incidence, prevalence, and mortality of diabetes mellitus in Wadena, Marshall, and Grand Rapids, Minnesota: the Three-City Study. Diabetes Care. 1986;9:343-350.
23. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59:750-755.
24. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
25. Brownlee M. Glycosylation of proteins and micro-angiopathy. Hosp Pract (Off Ed). 1992;27:46-50.
26. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care. 1992;15:1902-1925.
27. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836-842.
28. Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med. 1996;124:86-89.
29. Stolk RP, Vingerling JR, de Jong PT, et al. Retinopathy, glucose, and insulin in an elderly population: the Rotterdam study. Diabetes. 1995;44:11-15.
30. Nathan DM, Singer DE, Godine JE, Harrington CH, Perlmuter LC. Retinopathy in older type II diabetics: association with glucose control. Diabetes. 1986;35:797-801.
31. Morisaki N, Watanabe S, Kobayashi J, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc. 1994;42:142-145.
32. Chen MS, Kao CS, Fu CC, Chen CJ, Tai TY. Incidence and progression of diabetic retinopathy among non-insulin-dependent diabetic subjects:a4-yearfollow-up. Int J Epidemiol. 1995;24:787-795.
33. Liu QZ, Pettitt DJ, Hanson RL, et al. Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses. Diabetologia. 1993;36:428-432.
34. Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care. 1988;11:246-251.
35. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes. 1988;37:878-884.
36. Ballard DJ, Melton LJD, Dwyer MS, et al. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care. 1986; 9:334-342.
37. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of diabetic complications in relation to risk factors. Diabetes. 1986;35: 1332-1339.
38. Klein R, Klein BE, Moss SE. Incidence of gross proteinuria in older-onset diabetes: a population-based perspective. Diabetes. 1993;42:381-389.
39. Wirta O, Pasternack A, Laippala P, Turjanmaa V, Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol. 1996;45:10-17.
40. Ballard DJ, Humphrey LL, Metton LJ III, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes. 1988;37:405-412.
41. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. KidneyInt. 1982;21:730-738.
42. Lehtinen JM, Uusitupa M, Siitonen O, Pyörälä K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes. 1989;38:1307-1313.
43. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124 (suppl 1, pt 2):90-96.
44. Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1995;155:665-667.
45. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1982;31: 1-81.
46. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care. 1987;10:1-19.
47. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:104-109.
48. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
49. Nelson RG, Pettitt DJ, Baird HR, et al. Prediabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1993;36:998-1001.
50. Kasiske BL, Kalikl RSN, Ma JZ. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-138.
51. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care. 1995; 18:1113-1123.
52. Levin SR, Coburn J, Abraira C, et al. Glycemic control retards the progression of albuminuria in NIDDM. Diabetes. 1996;45(suppl 2):3A. Abstract.
53. Emanuele N, Klein R, Colwell J, et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes(VA CSDM). Diabetes Care. 1996;19:1375-1381.
54. Harris MI. Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med. 1996; 124:117-122.
55. Michigan Diabetes Research and Training Center. Diabetes in Communities. Ann Arbor, Mich: University of Michigan; 1992;2.
56. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl. 1985;701:38-52.
57. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154-160.
58. Despres JP, Lamarche B, Mauriege P, et al. Hyper-insulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
59. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19: 205-210.
60. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl. 1985;15:41-46.
61. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinaemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia. 1992; 35:766-770.
62. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol. 1994;140:857-869.
63. Liu QZ, Knowler WC, Nelson RG, et al. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians: cross-sectional and prospective analyses. Diabetes. 1992; 41:1141-1150.
64. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-1184.
65. Collins VR, Dowse GK, Zimmet PZ, et al. Serum insulin and ECG abnormalities suggesting coronary heart disease in the populations of Mauritius and Nauru: cross-sectional and longitudinal associations. J Clin Epidemiol. 1993;46:1373-1393.
66. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79-84.
67. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia and coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetoiogia. 1991; 34:356-361.
68. United Kingdom Prospective Diabetes Study Group. U. K. prospective diabetes study 16: overview of 6 years' therapy of type 11 diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
69. Henry RR, Genuth S. Forum one: current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:175-177.
70. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549.
71. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor. Diabetes Care. 1995;18:1299-1304.
72. Stern MP. The insulin resistance syndrome: the controversy is dead, long live the controversy. Diabetologia. 1994;37:956-958.
73. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetoiogia. 1994;37:945-947.
74. Sato Y, Shiraishi S, Oshida Y, Ishiguro T, Sakamoto N. Experimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar rats. Diabetes. 1989;38:91-96.
75. Stout RW. Insulin stimulation of cholesterol synthesis by arterial tissue. Lancet. 1970;1:248.
76. Stout RW, Buchanan KD, Vallance-Owen J. Arterial lipid metabolism in relation to blood glucose and plasma insulin in rats with streptozotocin-induced diabetes. Diabetologia. 1972;8:396-401.
77. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res. 1975;36:319-327.
78. Leonetti F, Iozzo P, Giaccari A, et al. Absence of clinically overt atherosclerotic vascular disease and adverse changes in cardiovascular risk factors in 70 patients with insulinoma. J Endocrinol Invest. 1993;16:875-880.
79. Tomono S, Kato N, Utsugi T, et al. The role of insulin in coronary atherosclerosis. Diabetes Res Clin Pract. 1994;22:117-122.
80. Mookherjee S, Potts JL, Hill NE, et al. Lack of relationship between plasma insulin and glucagon levels and angiographically-documented coronary atherosclerosis. Atherosclerosis. 1984;53: 99-109.
81. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;125:653-657.
82. Brownlee M. Nonenzymatic glycosylation of macromolecules: prospects of pharmacologic modulation. Diabetes. 1992;41:57-60.
83. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosytation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90:6434-6438.
84. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994;91:9441-9445.
85. Yegin A, Ozben T, Yegin H. Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res. 1995;25:157-161.
86. Colwell JA, Vascular thrombosis in type II diabetes mellitus. Diabetes. 1993;42:8-11.
87. Davi G, Catalano I, Averna M. et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769-1774.
88. Aoki I, Shimoyama K, Aoki N, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol. 1996; 27:560-566.
89. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994;17:818-823.
90. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki JH. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis. 1988;8:168-177.
91. Agardh CD, Nilsson EP, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care. 1982;5:322-325.
92. Stern MP, Haffner SM. Dyslipidemia in type II diabetes: implications for therapeutic intervention. Diabetes Care. 1991;14:1144-1159.
93. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995; 44:1303-1309.
94. Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care. 1995;18:1534-1543.
95. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994; 154:2473-2479.
96. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
97. Fu CC, Chang CJ, Tseng CH, et al. Development of macrovascular diseases in NIDDM patients in northern Taiwan: a 4-yr follow-up study. Diabetes Care. 1993;16:137-143.
98. Donahue RP, Abbott RD, Reed DM, Yano K. Post-challenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes. 1987;36:689-692.
99. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes. 1992;41:202-208.
100. Nielsen NV, Ditzel J. Prevalence of macro- and microvascular disease as related to glycosylated hemoglobin in type I and II diabetic subjects: an epidemiologic study in Denmark. Horm Metab Res Suppl. 1985;15:19-23.
101. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
102. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894-903.
103. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA. 1980;243:450-457.
104. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus: implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med. 1996;124:131-135.
105. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751-755.
106. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS), 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
107. Thompson CJ, Cummings J, Chalmers J, Gould C, Newton RW. Mow have patients reacted to the DCCT? Diabetes Care. 1996;19:876-879.
108. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993; 16:21-31.
109. Wolfenbuttel B, Sels J, Rondas-Colbers G, Menheere P, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care. 1996;19:1326-1332.
110. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.
111. Yki JH, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-1433.
112. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care. 1996;19:195-203.
113. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1996;19(suppl);S8-15.
114. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161-1165.
115. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438-443.
116. Freedman BI, Tuttle AB, Spray BJ. Familial pre-disposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1995;25:710-713.
117. Panzram G, Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-131.
118. Knuiman MW, Welborn TA, Whittall DE. An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus using the Cox proportional hazards regression model. Am J Epidemiol. 1992;135:638-648.
119. Grady MD, Rubin SM, Petitti DB, Fox CS. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117:1016-1037.
120. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995; 332:1251-1255.
121. Colwell JA. DCCT findings: applicability and implications for NIDDM. Diabetes Rev. 1994;2: 277-291.